Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Continuing HIV therapy in the ICU.

N Soni1, A Pozniak

  • 1Chelsea & Westminster NHS Trust, London, UK. n.soni@ic.ac.uk

Critical Care (London, England)
|December 12, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Frailty, Geriatric Impairments, and Quality of Life in Older Cancer Survivors Compared to Age-Matched Non-Cancer Controls.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same author

British HIV Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of non-tuberculous mycobacteria 2024.

HIV medicine·2025
Same author

Update from the 5th Edition of the WHO Classification of Nasal, Paranasal, and Skull Base Tumors: Imaging Overview with Histopathologic and Genetic Correlation.

AJNR. American journal of neuroradiology·2023
Same author

Unpacking the CNS Manifestations of Epstein-Barr Virus: An Imaging Perspective.

AJNR. American journal of neuroradiology·2023
Same author

Amino Acid Tracer PET MRI in Glioma Management: What a Neuroradiologist Needs to Know.

AJNR. American journal of neuroradiology·2023
Same author

Diagnostic Performance of PET and Perfusion-Weighted Imaging in Differentiating Tumor Recurrence or Progression from Radiation Necrosis in Posttreatment Gliomas: A Review of Literature.

AJNR. American journal of neuroradiology·2020

Stopping antiretroviral therapy (ART) in intensive care unit (ICU) patients poses significant risks, including drug resistance and increased immunosuppression. Further research is crucial to understand and manage these complex challenges in critically ill patients.

Area of Science:

  • Critical Care Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Antiretroviral therapy (ART) management in intensive care unit (ICU) patients is challenging due to limited parenteral formulations.
  • Sudden cessation of ART may lead to viral rebound, increased immunosuppression, and potential drug resistance.
  • Drug interactions with cytochrome P450 3A4 and inherent drug toxicities complicate ART use in the ICU.

Purpose of the Study:

  • To evaluate the unmeasured risks and benefits of discontinuing antiretroviral therapy in critically ill patients admitted to the ICU.
  • To highlight the clinical challenges and knowledge gaps in managing HIV-infected patients requiring intensive care.

Main Methods:

  • This review synthesizes current knowledge on the implications of stopping ART in the ICU setting.

Related Experiment Videos

  • Analysis of pharmacokinetic properties, drug interactions, and toxicity profiles of antiretroviral agents.

    • Main Results:

    • Parenteral ART options are limited, often necessitating treatment interruption.
    • Potential for rapid development of drug resistance due to long drug half-lives and viral load rebound.
    • Impaired enteral absorption and significant drug-drug interactions with commonly used ICU medications.

    Conclusions:

    • Stopping ART in the ICU presents substantial risks including resistance and immunosuppression, with limited data on benefits.
    • The need for further research into optimal ART management strategies for critically ill patients is emphasized.
    • Understanding drug metabolism, toxicity, and resistance patterns is vital for improving patient outcomes.